

**IN THE CLAIMS**

Please amend the claims as follows.

1. (Currently Amended) A method of stimulating a HIV1-specific CD8<sup>+</sup> response in a human infected with an HIV retrovirus said method comprising:  
administering to the human, ~~a~~ an attenuated recombinant pox virus, which enters the cells of the human and intracellularly produces HIV specific peptides for presentation on the cell's MHC class I molecules,  
where said peptides are presented in an amount sufficient to stimulate ~~a protective CD8<sup>+</sup>~~ HIV antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> responses ~~response~~, and  
where said human
  - i. has a viral load of less than 10,000 viral copies per ml of plasma and a CD4<sup>+</sup> cell count of above 500 cells/ml, and
  - ii. has been treated with one or more anti-viral agents, which contributed to a lower viral copy and higher CD4<sup>+</sup> cell count than before treatmentwhere said HIV specific peptides comprise HIV Gag, Gp120, Nef or Pol peptides.
2. (Previously Presented) A method of claim 1 wherein the human has been treated with anti-viral agents, which resulted in the human having a viral load of less than 1,000 viral copies per ml of blood serum and a CD4<sup>+</sup> cell count of above 500 cells/ml.
3. (Original) A method of claim 2 wherein the anti-viral agents comprise a combination of protease inhibitors and inhibitors of reverse transcriptase.
4. (Canceled)
5. (Canceled)
6. (Canceled)

7. (Currently Amended) A method of claim 1 ~~[[6]]~~ wherein the attenuated recombinant pox virus comprises NYVAC or ALVAC.

8. (Currently Amended) A method of claim 1 ~~[[6]]~~ wherein the recombinant pox virus comprises MVA.

9. (Currently Amended) A method of claim 1 where the attenuated recombinant pox virus vaccine is administered a second time.

10. (Previously Presented) A method of claim 1 wherein the HIV specific peptides are structural viral peptides.

11. (Canceled)

12. (Currently Amended) A method of claim 1 wherein the method ~~vaccine~~ further comprises administering an adjuvant.

13. (Original) A method of claim 1 further comprising administering interleukin 2 or CD40 ligand in an amount sufficient to potentiate the CD8<sup>+</sup> response.

14. (Previously Presented) A method of claim 1 where the human has been infected with HIV and has demonstrated repeated and sustained proliferative T-cell responses to Gp120 envelope protein.

15. (Previously Presented) A method of claim 14 where the human has demonstrated repeated and sustained proliferative T-cell responses to p24 Gag antigen.

16. (Previously Presented) A method of claim 1 where the human is infected with HIV and is further tested by a skin test for a hypersensitive response to p24 Gag antigen.

17. (Previously Presented) A method of claim 1 where the human is infected with HIV and is further tested by a skin test for a hypersensitive response to Gp120 envelope antigen.

18. (Currently Amended) A method of maintaining a reduced viral load in a mammal infected with an immunodeficiency retrovirus said method comprising:

administering to the mammal a an attenuated recombinant pox virus, which enters the cells of the mammal and intracellularly produces immunodeficiency retroviral specific peptides for presentation on the cell's MHC class I molecules,

where said peptides are presented in an amount sufficient to stimulate ~~a protective CD8<sup>+</sup>~~ HIV antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> responses ~~response~~, and thereby maintain a reduced viral load in the mammal, and

where said mammal

i. has an immunodeficiency retroviral load of less than 10,000 viral copies per ml of plasma and a CD4<sup>+</sup> cell count of above 500 cells/ml prior to administration of the recombinant virus, and

ii. has been treated with one or more anti-viral agents, which contributed to a lower viral copy and higher CD4<sup>+</sup> cell count before treatment

where said peptides comprise immunodeficiency retroviral Gag, Gp120, Nef or Pol peptides.

19. (Canceled)

20. (Currently Amended) A method of stimulating a HIV1-specific CD8<sup>+</sup> response in a human infected with an HIV retrovirus said method comprising:

administering to the human, a an attenuated recombinant pox virus, which enters the cells of the human and intracellularly produces HIV specific peptides for presentation on the cell's MHC class I molecules,

where said peptides are presented in an amount sufficient to stimulate ~~a protective CD8<sup>+</sup>~~ HIV antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> responses ~~response~~, and

where said human

i. has a viral load of less than 10,000 viral copies per ml of plasma and a CD4<sup>+</sup> cell count of above 500 cells/ml, and

ii. has been treated with one or more anti-viral agents, which contributed to a lower viral copy and higher CD4<sup>+</sup> cell count than before treatment

where said HIV specific peptides comprise Gag, Pol, Env peptides or a combination thereof.

21. (New) The method of claim 2, wherein anti-viral treatment is reduced or stopped after administering the recombinant virus.

22. (New) The method of claim 2, wherein anti-viral treatment is interrupted after administering the recombinant virus.